BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 29892061)

  • 21. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Mardinian K; Adashek JJ; Botta GP; Kato S; Kurzrock R
    Mol Cancer Ther; 2021 Dec; 20(12):2341-2351. PubMed ID: 34642211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.
    Rodriguez-Nieto S; Cañada A; Pros E; Pinto AI; Torres-Lanzas J; Lopez-Rios F; Sanchez-Verde L; Pisano DG; Sanchez-Cespedes M
    Hum Mutat; 2011 Feb; 32(2):E1999-2017. PubMed ID: 21280140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene silencing associated with SWI/SNF complex loss during NSCLC development.
    Song S; Walter V; Karaca M; Li Y; Bartlett CS; Smiraglia DJ; Serber D; Sproul CD; Plass C; Zhang J; Hayes DN; Zheng Y; Weissman BE
    Mol Cancer Res; 2014 Apr; 12(4):560-70. PubMed ID: 24445599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SWI/SNF complexes are required for full activation of the DNA-damage response.
    Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
    Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
    Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
    Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
    Medina PP; Sanchez-Cespedes M
    Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.
    Romero OA; Verdura S; Torres-Diz M; Gomez A; Moran S; Condom E; Esteller M; Villanueva A; Sanchez-Cespedes M
    Oncogene; 2017 Mar; 36(9):1287-1296. PubMed ID: 27593925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer.
    Huang HT; Chen SM; Pan LB; Yao J; Ma HT
    Oncol Rep; 2015 Jan; 33(1):283-91. PubMed ID: 25370573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
    Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [SMARCA4-deficient thoracic tumors: A new entity].
    Decroix E; Leroy K; Wislez M; Fournel L; Alifano M; Damotte D; Mansuet-Lupo A
    Bull Cancer; 2020 Jan; 107(1):41-47. PubMed ID: 31916995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates.
    Mei L; Alikhan M; Mujacic I; Parilla M; Antic T
    Acta Cytol; 2019; 63(5):438-444. PubMed ID: 31230044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
    Fukumoto T; Magno E; Zhang R
    Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
    Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
    Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
    Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives and Issues in the Assessment of
    Armon S; Hofman P; Ilié M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
    Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
    Front Immunol; 2021; 12():762598. PubMed ID: 34675941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.